Background: CD-19 Chimeric Antigen Receptor – T (CAR-T) cell therapy is FDA approved for the treatment of primary refractory or recurrent Diffuse Large B-Cell Lymphoma (DLBCL) after two or more lines of systemic therapies have failed. The two commercially available products are Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel). In clinical trials, 54% of 111 patients […]

Case Presentation: 51 year old female with past medical history notable only for recent knee pain with intermittent NSAID use presented with melenic stools and one episode of coffee ground emesis.On presentation she was tachycardic and hypotensive with initial hemoglobin of 4.9 (units) with improvement in vital signs post blood transfusion. Initial CT abdomen/pelvis without […]